Pfizer's $53M drug under threat

The first generic version of Pfizer’s JAK inhibitor Xeljanz has been registered in Australia by Accelagen.

The TGA approved Accelagen’s generics of the 5mg strength and the 10mg strength under three brand names – Tofadoz, Tofacitinib Lupin, and MSN Tofacitinib.

In the year to April, Xeljanz earned Pfizer $53,174,589 million in pre-rebate PBS benefits, with the 5 mg strength contributing over $48.1 million to that figure.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here